Actrapid (insulin) NM solution for injections 100 IU/ml. 10 ml. vial №1

Description

Composition

Active substance: insulin solution (human genetically engineered) 100 IU/ml. 1 IU corresponds to 35 mcg of anhydrous human insulin.

Excipients: zinc chloride, glycerol, metacresol, hydrochloric acid and/or sodium hydroxide (to maintain pH), water d / i.

Pharmachologic effect

Aktrapid NM is a short-acting insulin preparation. Interacting with a specific receptor on the outer membrane of cells, it forms an insulin receptor complex. By increasing the synthesis of cAMP (in fat cells and liver cells) or directly penetrating into the cell (muscles), the insulin receptor complex stimulates intracellular processes, incl. synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthetase, etc.). The decrease in the concentration of glucose in the blood is due to an increase in its intracellular transport, increased absorption and absorption by tissues, stimulation of lipogenesis, glycogenogenesis, protein synthesis, a decrease in the rate of glucose production by the liver (decrease in glycogen breakdown), etc. After s / c injection, the effect occurs within 20-30 minutes, reaches a maximum after 1-3 hours and lasts, depending on the dose, 5-8 hours. The duration of the drug depends on the dose, method, site of administration and has significant individual characteristics .

Indications

insulin dependent diabetes mellitus

Contraindications

Hypersensitivity to the components of the drug, hypoglycemia.

Vials with the drug Actrapid NM can only be used together with insulin syringes, which are marked with a scale that allows you to measure the dose in units of action.

Vials with the drug Actrapid NM are intended for individual use only.

Before using the insulin solution, you must:

Check the label to make sure the correct type of insulin is selected.

Disinfect the rubber stopper with a cotton swab.

Actrapid NM should not be used in the following cases: in insulin pumps.

Patients need to be explained that if a new vial just received from a pharmacy does not have a protective cap or it does not fit tightly, such insulin must be returned to the pharmacy.

If it has not been stored correctly or if it has been frozen.

If it is no longer clear and colorless.